Top GME Redditor DeepFuckingValue Names HGEN As A Top Pick, Moving Pre-Market, GOVX, AVCT

DeepFuckingValue, also known as Roaring Kitty, is the prolific GME investor who has led the shorting squeeze charge. A Reddit poster recently broke down his top picks outside of GME, as shown in an image of his notebook:




The one that stands out the most is HGEN. At the time of this note, HGEN was $19.59. It closed yesterday at $16.92, below this price and the price of the $18.50 offering it just closed on Monday. HGEN announced Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19. The stock shot up to $29 on a short squeeze fueled rally after the news but pulled back as the company raised the $92.5 million. 

Usually investors view financing as bad news, but this is done with a distinct purpose. The company is going to be manufacturing Lenzilumab in advance of expected Emergency Use Authorization granted by the FDA. The timing of this grant is expected to happen in weeks, so speculative investors will be buying up the stock in anticipation of this decision. In addition to being one of DFV's top picks, HGEN remains a strong short squeeze candidate with a 26% short interest according to Yahoo Finance. The stock is up in pre-market after announcing it will present positive data for brain cancer therapy at AACR meeting.

Another stock that is up in the pre-market is GOVX. GOVX is the cheapest COVID stock with a $28 million market cap but has over $20 million in cash. It's working on a single dose vaccine that could be less susceptible to virus mutations. 

AVCT was up 29% yesterday after receiving an unsolicited bid to buy out the company at $9. It raced to $7.49 in the last few minutes of trading, but still sits at a good deal below the bid price. So if more developments occur to solidify the bid, it could hit $9 or higher if competing bids come up. 


Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more